Gossamer Bio, Inc.
GOSS
$0.16
-$0.02-11.23%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -19.59% | 71.45% | 47.13% | 40.23% | -88.01% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -19.59% | 71.45% | 47.13% | 40.23% | -88.01% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -19.59% | 71.45% | 47.13% | 40.23% | -88.01% |
| SG&A Expenses | 2.55% | 116.52% | 16.06% | 10.44% | 0.12% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -29.73% | 32.38% | 31.49% | 26.57% | 14.85% |
| Operating Income | 32.74% | -21.89% | -27.44% | -22.76% | -174.42% |
| Income Before Tax | 144.16% | -27.37% | -33.54% | -51.00% | -171.32% |
| Income Tax Expenses | -- | -- | 96.35% | -- | -- |
| Earnings from Continuing Operations | 144.16% | -27.37% | -43.02% | -56.55% | -177.74% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 144.16% | -27.37% | -43.02% | -56.55% | -177.74% |
| EBIT | 32.74% | -21.89% | -27.44% | -22.76% | -174.42% |
| EBITDA | 32.74% | -21.89% | -27.80% | -23.53% | -174.06% |
| EPS Basic | 131.35% | -23.41% | -43.00% | -55.40% | -177.39% |
| Normalized Basic EPS | 50.00% | -23.37% | -6.80% | -26.64% | -170.94% |
| EPS Diluted | 54.94% | -23.41% | -43.00% | -55.40% | -178.38% |
| Normalized Diluted EPS | 51.33% | -23.37% | -6.80% | -26.64% | -174.82% |
| Average Basic Shares Outstanding | 40.80% | 3.23% | 0.00% | 0.72% | 0.47% |
| Average Diluted Shares Outstanding | 44.66% | 3.23% | 0.00% | 0.72% | -4.72% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |